While our previous studies have shown that the resistance of HNSCC to CDDP-based therapy can be overcome with inhibition of TrkB pathways, the mechanisms for this phenomenon has yet to be elucidated [13]. Here, NTRK2 is linked to head and neck squamous cell carcinoma.